Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $12.91 and last traded at $12.85, with a volume of 31612 shares traded. The stock had previously closed at $12.60.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. KGaA in a research note on Thursday, May 15th.
Read Our Latest Stock Analysis on Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Stock Up 2.0%
The firm has a 50 day simple moving average of $11.75 and a two-hundred day simple moving average of $10.38. The stock has a market cap of $28.71 billion, a P/E ratio of 67.63 and a beta of 0.76. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.22 by $0.01. The business had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.41 billion. Equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current year.
Fresenius SE & Co. KGaA Increases Dividend
The company also recently disclosed a dividend, which was paid on Wednesday, June 4th. Investors of record on Wednesday, May 28th were issued a dividend of $0.1827 per share. This represents a dividend yield of 1.48%. This is a positive change from Fresenius SE & Co. KGaA's previous dividend of $0.17. The ex-dividend date of this dividend was Tuesday, May 27th. Fresenius SE & Co. KGaA's dividend payout ratio (DPR) is currently 94.74%.
Fresenius SE & Co. KGaA Company Profile
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
